Axonics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXNX research report →
Companywww.axonics.com
Axonics, Inc. , a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention.
- CEO
- Raymond W. Cohen
- IPO
- 2018
- Employees
- 797
- HQ
- Irvine, CA, US
Price Chart
Valuation
- Market Cap
- $3.63B
- P/E
- -572.24
- P/S
- 9.90
- P/B
- 5.46
- EV/EBITDA
- 456.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.94%
- Op Margin
- -7.11%
- Net Margin
- -1.66%
- ROE
- -1.01%
- ROIC
- -2.68%
Growth & Income
- Revenue
- $366.38M · 33.86%
- Net Income
- $-6,088,000 · 89.80%
- EPS
- $-0.12 · 90.63%
- Op Income
- $-26,057,000
- FCF YoY
- -675.00%
Performance & Tape
- 52W High
- $70.98
- 52W Low
- $70.98
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.83
- Avg Volume
- 0
Get TickerSpark's AI analysis on AXNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 24 | Kiernan Jane E | sell | 19,861 |
| Nov 15, 24 | Woock John | sell | 13,125 |
| Nov 15, 24 | Woock John | sell | 3,581 |
| Nov 15, 24 | Woock John | sell | 15,555 |
| Nov 15, 24 | Woock John | sell | 77,403 |
| Nov 15, 24 | snyderman nancy lynn MD | sell | 14,944 |
| Nov 15, 24 | snyderman nancy lynn MD | sell | 4,167 |
| Nov 15, 24 | snyderman nancy lynn MD | sell | 10,000 |
| Nov 15, 24 | Sama Rinda | sell | 608 |
| Nov 15, 24 | Sama Rinda | sell | 9,962 |
Our AXNX Coverage
We haven't published any research on AXNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AXNX Report →